Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Carr Financial Group Corp

Carr Financial Group Corp increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 5.1% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 2,100 shares of the company’s stock after purchasing an additional 101 shares during the quarter. Carr Financial Group Corp’s holdings in Novo Nordisk A/S were worth $250,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Lindbrook Capital LLC boosted its position in Novo Nordisk A/S by 3.3% in the 3rd quarter. Lindbrook Capital LLC now owns 10,735 shares of the company’s stock valued at $1,278,000 after buying an additional 346 shares during the period. Bridges Investment Management Inc. increased its holdings in shares of Novo Nordisk A/S by 2.0% in the 3rd quarter. Bridges Investment Management Inc. now owns 7,700 shares of the company’s stock valued at $917,000 after acquiring an additional 150 shares during the last quarter. Wealth Quarterback LLC acquired a new stake in Novo Nordisk A/S during the third quarter worth approximately $856,000. Assetmark Inc. lifted its position in Novo Nordisk A/S by 5.1% in the third quarter. Assetmark Inc. now owns 441,882 shares of the company’s stock valued at $52,615,000 after acquiring an additional 21,553 shares during the last quarter. Finally, Verdence Capital Advisors LLC boosted its position in shares of Novo Nordisk A/S by 18.9% in the 3rd quarter. Verdence Capital Advisors LLC now owns 42,977 shares of the company’s stock valued at $5,117,000 after purchasing an additional 6,821 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Finally, StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Stock Down 0.4 %

NVO stock opened at $107.20 on Friday. Novo Nordisk A/S has a one year low of $94.73 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. The company has a fifty day moving average of $121.42 and a 200-day moving average of $130.30. The stock has a market capitalization of $481.06 billion, a PE ratio of 34.69, a price-to-earnings-growth ratio of 1.44 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 89.69% and a net margin of 35.03%. The business had revenue of $9.82 billion for the quarter, compared to analyst estimates of $9.91 billion. As a group, analysts expect that Novo Nordisk A/S will post 2.87 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.